Preventing low platelets from chemo for nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests if Hetrombopag can prevent low blood platelets caused by gemcitabine and cisplatin chemotherapy for nasopharyngeal carcinoma. It may help patients who had low platelets in a previous chemo cycle.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer confirmed by a biopsy or cell test.
- You are 18 to 75 years old.
- You are getting gemcitabine plus cisplatin chemo in 21-day cycles and had low platelets (under 75) in your last cycle.
- Your doctor expects you to get at least 2 more cycles of the same chemo.
- Your overall health is good enough for daily activities (ECOG score 0-2).
- You have not had other blood or bleeding disorders, recent blood clots, or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called hetrombopag to see if it can prevent low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. It may help you avoid treatment delays or dose reductions.
This trial tests a new drug called Romiplostim N01 to see if it works better than the standard treatment (recombinant human thrombopoietin) for raising low platelets caused by cancer therapies, when other treatments have failed. It is for people aged 18-75 with solid tumors or blood cancers who have not responded to at least two platelet growth factors.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This trial tests a drug called Hetrombopag to see if it can prevent low platelet counts in people with advanced lung cancer who are receiving certain types of chemotherapy. The goal is to help keep platelet levels safe so you can continue your cancer treatment without delays or dose reductions.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This trial tests a pill called herombopag to prevent low platelets caused by chemo and radiation for cervical cancer. The goal is to see if it can help keep your platelet levels safe so you can complete your treatment.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.